- Home
- HMY vs ROIV Comparison
HMY vs ROIV Comparison
Compare HMY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- ROIV
- Stock Information
- Founded
- HMY 1950
- ROIV 2014
- Country
- HMY South Africa
- ROIV United Kingdom
- Employees
- HMY N/A
- ROIV N/A
- Industry
- HMY Precious Metals
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- HMY Basic Materials
- ROIV Health Care
- Exchange
- HMY Nasdaq
- ROIV Nasdaq
- Market Cap
- HMY 7.5B
- ROIV 8.4B
- IPO Year
- HMY N/A
- ROIV N/A
- Fundamental
- Price
- HMY $17.55
- ROIV $10.15
- Analyst Decision
- HMY Sell
- ROIV Buy
- Analyst Count
- HMY 3
- ROIV 4
- Target Price
- HMY $6.60
- ROIV $17.50
- AVG Volume (30 Days)
- HMY 7.8M
- ROIV 8.0M
- Earning Date
- HMY 01-01-0001
- ROIV 05-29-2025
- Dividend Yield
- HMY 0.85%
- ROIV N/A
- EPS Growth
- HMY 16.30
- ROIV N/A
- EPS
- HMY 0.88
- ROIV N/A
- Revenue
- HMY $3,553,951,394.00
- ROIV $122,585,000.00
- Revenue This Year
- HMY $17.62
- ROIV N/A
- Revenue Next Year
- HMY $7.93
- ROIV N/A
- P/E Ratio
- HMY $19.40
- ROIV N/A
- Revenue Growth
- HMY 16.84
- ROIV 140.04
- 52 Week Low
- HMY $7.97
- ROIV $8.73
- 52 Week High
- HMY $18.77
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- HMY 72.73
- ROIV 50.07
- Support Level
- HMY $16.54
- ROIV $9.90
- Resistance Level
- HMY $18.77
- ROIV $10.26
- Average True Range (ATR)
- HMY 0.89
- ROIV 0.47
- MACD
- HMY 0.32
- ROIV 0.06
- Stochastic Oscillator
- HMY 80.32
- ROIV 92.81
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.